A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

They found that taking SGLT-2 inhibitors was linked to a 35% lower risk of developing dementia in comparison to those on ...

The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.